Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710860 | 0.87 | TMPRSS2 (0.38) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL26832567 | 0.86 | TMPRSS2 (0.37) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL16699384 | 0.86 | ALDH1A1 (0.33) | TMPRSS2ALDH1A1 | |
| SCHEMBL16708535 | 0.85 | PI4KA (0.39) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL16698782 | 0.82 | TMPRSS2 (0.33) | TMPRSS2 | |
| SCHEMBL16710454 | 0.82 | PI4KA (0.47) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13532207 | 0.82 | PI4KA (0.47) | TMPRSS2PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18571686 | 0.80 | PI4KA (0.37) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL15606983 | 0.79 | ADORA3 (0.49) | ADORA3 | |
| SCHEMBL23803200 | 0.78 | TMPRSS2 (0.38) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4122932-A1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3505173-B1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-10377761-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| EP-3505173-A1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-3068405-B1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190055253-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-02-21 | — | — | US | disclosed |
| US-10059716-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180016280-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2018-01-18 | — | — | US | disclosed |
| US-9701682-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170008897-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-3068405-A1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| US-9388208-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| WO-2015069939-A1 | PYRROLO [1,2,F] [1,2,4] TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133395-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | ROSEMOUNT INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008897-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | TMPRSS2 20/4885PI4KA 3453/4885PI4K2B 2572/4885 |
| US-20180016280-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | TMPRSS2 20/4885PI4KA 3453/4885PI4K2B 2572/4885 |
| US-20150133395-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | TMPRSS2 20/4885PI4KA 3453/4885PI4K2B 2572/4885 |
| US-10377761-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | SYNJ1, SARS1, SYNJ2 | TMPRSS2 20/4885PI4KA 3453/4885PI4K2B 2572/4885 |
| US-10059716-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | SYNJ1, SARS1, SYNJ2 | TMPRSS2 20/4885PI4KA 3453/4885PI4K2B 2572/4885 |
| US-20190055253-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | TMPRSS2 20/4885PI4KA 3453/4885PI4K2B 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.